STOCKWATCH: Running the gamut of commotions from A to A
This article was originally published in Scrip
Executive Summary
As the third quarter earnings season got under way last week, bad news across the sector seemed to be focused on companies with names starting at the front of the alphabet, like Ariad, AMAG, Alimera Sciences and Amarin. But away from 'A', Johnson & Johnson's continuing good performance raised interesting questions not only for pharmaceutical firms, but also for their competitors in the devices or diagnostics sectors.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.